SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-046849
Filing Date
2022-08-11
Accepted
2022-08-11 16:02:12
Documents
51
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0622_tffpharma.htm   iXBRL 10-Q 484479
2 CERTIFICATION f10q0622ex31-1_tffpharma.htm EX-31.1 12781
3 CERTIFICATION f10q0622ex31-2_tffpharma.htm EX-31.2 12861
4 CERTIFICATION f10q0622ex32-1_tffpharma.htm EX-32.1 6421
5 GRAPHIC image_001.jpg GRAPHIC 8232
  Complete submission text file 0001213900-22-046849.txt   2998604

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE tffp-20220630.xsd EX-101.SCH 43447
7 XBRL CALCULATION FILE tffp-20220630_cal.xml EX-101.CAL 23532
8 XBRL DEFINITION FILE tffp-20220630_def.xml EX-101.DEF 146809
9 XBRL LABEL FILE tffp-20220630_lab.xml EX-101.LAB 335471
10 XBRL PRESENTATION FILE tffp-20220630_pre.xml EX-101.PRE 157433
45 EXTRACTED XBRL INSTANCE DOCUMENT f10q0622_tffpharma_htm.xml XML 289965
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39102 | Film No.: 221155560
SIC: 2834 Pharmaceutical Preparations